On July 10, 2019, the Federal Circuit ruled in favor of researchers from Chinese University of Hong Kong, finding that researchers from Stanford University who owned a fetal DNA testing patent did not include a vital part of its method for detecting Down syndrome in its written description. Therefore, the patent was ruled invalid, upholding the earlier Patent Trial and Appeal Board (PTAB) decision. Finnegan represented the researchers from Chinese University.
The case began in 2014 after the Chinese University researchers submitted a patent application covering a method for detecting chromosomal abnormality in fetuses. The Stanford University researchers then reworked their earlier filing of a similar application, which used target-based sequencing, to try and encompass the Chinese University researchers' method, which used random sequencing. However, the Stanford University researchers did not disclose the random sequencing method in their patent's specification—the specification described using targeted sequences, which rendered the patent invalid.
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.